UroGen Pharma (URGN) Free Cash Flow (2017 - 2026)
UroGen Pharma's (URGN) quarterly Free Cash Flow came in at -$47.6 million in Q1 2026, down 13.97% YoY from -$55.4 million in Q1 2025, and down 29.74% on a QoQ basis from -$36.7 million in Q4 2025.
UroGen Pharma (URGN) Free Cash Flow (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of Free Cash Flow data on file, last reported at -$47.6 million in Q1 2026.
- Quarterly Free Cash Flow fell 13.97% year-over-year to -$47.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$172.9 million (down 62.57% YoY) and the FY2025 annual result came in at -$167.0 million, down 75.22% from the prior year.
- Free Cash Flow retreated to -$47.6 million in Q1 2026, from -$36.7 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$13.0 million in Q4 2023 to a low of -$48.2 million in Q3 2025.
- A 5-year average of -$27.9 million and a median of -$24.5 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow soared 41.04% — and 2025, when it sank 165.41%.
- Tracing URGN's Free Cash Flow over 5 years: stood at -$22.0 million in 2022, then soared by 41.04% to -$13.0 million in 2023, then declined by 6.58% to -$13.8 million in 2024, then sank by 165.41% to -$36.7 million in 2025, then retreated by 29.74% to -$47.6 million in 2026.
- The last three Free Cash Flow figures came in at -$47.6 million (Q1 2026), -$36.7 million (Q4 2025), and -$48.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | -34.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.27 Mn |
| Jun 30, 2026 | -34.27 Mn |
| Mar 31, 2026 | -47.65 Mn |
| Mar 31, 2026 | -47.65 Mn |
| Dec 31, 2025 | -36.73 Mn |
| Dec 31, 2025 | -36.73 Mn |
| Sep 30, 2025 | -48.23 Mn |
| Sep 30, 2025 | -48.23 Mn |
| Jun 30, 2025 | -40.26 Mn |
| Jun 30, 2025 | -40.26 Mn |
| Mar 31, 2025 | -41.81 Mn |
| Mar 31, 2025 | -41.81 Mn |
| Dec 31, 2024 | -13.84 Mn |
| Dec 31, 2024 | -13.84 Mn |
| Sep 30, 2024 | -27.36 Mn |
| Sep 30, 2024 | -27.36 Mn |
| Jun 30, 2024 | -23.32 Mn |
| Jun 30, 2024 | -23.32 Mn |
| Mar 31, 2024 | -30.80 Mn |
| Mar 31, 2024 | -30.80 Mn |